Heparin‐binding epidermal growth factor‐like growth factor as a novel targeting molecule for cancer therapy

@article{Miyamoto2006HeparinbindingEG,
  title={Heparin‐binding epidermal growth factor‐like growth factor as a novel targeting molecule for cancer therapy},
  author={Shingo Miyamoto and Hiroshi Yagi and Fusanori Yotsumoto and Tatsuhiko Kawarabayashi and Eisuke Mekada},
  journal={Cancer Science},
  year={2006},
  volume={97}
}
HB‐EGF, a member of the EGF family of growth factors, exerts its biological activity through activation of the EGFR and other ErbB receptors. HB‐EGF participates in diverse biological processes, including heart development and maintenance, skin wound healing, eyelid formation, blastocyst implantation, progression of atherosclerosis and tumor formation, through the activation of signaling molecules downstream of ErbB receptors and interactions with molecules associated with HB‐EGF. Recent… 

Heparin-binding epidermal growth factor-like growth factor as a new target molecule for cancer therapy.

TLDR
Several lines of evidence have indicated that HB-EGF plays a key role in the acquisition ofmalignant phenotypes, such as tumorigenicity, invasion, metastasis and resistance to chemotherapy.

Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy.

  • C. LianL. Ruan Z. Tu
  • Biology, Medicine
    Cancer biotherapy & radiopharmaceuticals
  • 2016
TLDR
The importance of HB-EGF in mammary carcinoma progression and the potential value of HB -EGF as a therapeutic target for breast cancer treatment are discussed.

Heparin-Binding Epidermal Growth Factor-Like Growth Factor as a Potent Target for Breast Cancer Therapy

TLDR
The importance of HB-EGF in mammary carcinoma progression and the potential value of HB -EGF as a therapeutic target for breast cancer treatment are discussed.

Targeting the heparin-binding epidermal growth factor-like growth factor in ovarian cancer therapy

TLDR
The possibility of the clinical adaptation of targeting against heparin-binding epidermal growth factor-like growth factor (HB-EGF), one of the ligands of the ErbB system, in ovarian cancer therapy is discussed.

Essential Roles of Heparin‐Binding Epidermal Growth Factor‐Like Growth Factor in the Brain

TLDR
Findings suggest that HB‐EGF contributes to the neuronal survival and proliferation of glial/stem cells and promotes the survival of dopaminergic neurons, an action mediated by mitogen‐activated protein kinase (MAPK) as well as by the Akt signaling pathway.

Heparin-binding epidermal growth factor–like growth factor promotes transcoelomic metastasis in ovarian cancer through epithelial-mesenchymal transition

TLDR
Heparin-binding epidermal growth factor–like growth factor is a mutual validating target in the peritoneal dissemination of ovarian cancer, and CRM197 may be useful as a anticancer agent for advanced ovarian cancer.

Heparin-binding epidermal growth factor-like growth factor is a potent regulator of invasion activity in oral squamous cell carcinoma

TLDR
Data indicate that HB-EGF released from HSC3 cells by TACE stimulates EGFR in an autocrine manner, which in turn activates invasion activity via MMP-9 upregulation.

Heparin‐binding epidermal growth factor‐like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome

TLDR
In bladder cancer, overexpression of both HB‐EGF and EGFR have been observed, but to the authors' knowledge the prognostic significance of different modes of HB‐ EGF signaling have remained unclear.

Proteolytic activation of heparin‐binding EGF‐like growth factor by membrane‐type matrix metalloproteinase‐1 in ovarian carcinoma cells

TLDR
Results indicate that MT1‐MMP co‐expressed with HB‐EGF in ovarian carcinoma cells potentiates the activity of HB‐ EGF to promote invasive tumor growth and spreading in vivo.

Synergistic anti‐tumor effect of paclitaxel with CRM197, an inhibitor of HB‐EGF, in ovarian cancer

TLDR
Investigation of the anti‐tumor effects of paclitaxel, as an anti‐cancer agent, and CRM197, as a specific inhibitor off HB‐EGF, in ovarian cancer finds inhibitory agents against HB‐ EGF represent possible chemotherapeutic and chemosensitizing agents for ovarian cancer.
...

References

SHOWING 1-10 OF 77 REFERENCES

Heparin-binding epidermal growth factor-like growth factor stimulates mitogenic signaling and is highly expressed in human malignant gliomas

TLDR
Results indicate that heparin-binding EGF-like growth factor and proHB-EGF contribute to the growth of human malignant glioma cells, most likely through autocrine and juxtacrine mechanisms.

HB-EGF Is a Potent Inducer of Tumor Growth and Angiogenesis

TLDR
Findings establish s-HB-EGF as a potent inducer of tumor growth and angiogenesis and suggest that therapeutic intervention aimed at the inhibition of s- HB- EGF functions may be useful in cancer treatment.

Clinical significance of heparin-binding epidermal growth factor-like growth factor in peritoneal fluid of ovarian cancer

TLDR
In peritoneal fluid, HB- EGF is sufficiently elevated to activate cancer cells even at an early stage of OVCA, suggesting that HB-EGF might play a key role in cell survival and in the proliferation of OvCA.

Heparin-binding EGF-like growth factor.

N‐arginine dibasic convertase is a specific receptor for heparin‐binding EGF‐like growth factor that mediates cell migration

TLDR
It is suggested that N‐arginine dibasic convertase (NRDc) is a novel specific receptor for HB‐EGF that modulates HB‐ EGF‐induced cell migration via erbB1.

Clinical Significance of Heparin-Binding Epidermal Growth Factor–Like Growth Factor and A Disintegrin and Metalloprotease 17 Expression in Human Ovarian Cancer

TLDR
It is suggested that heparin-binding EGF-like growth factor (HB-EGF) and other EGFR ligands and ADAM 17 contribute to the progression of ovarian cancer and that HB- EGF plays a pivotal role in the aggressive behavior of a tumor in ovarian cancer.

Heparin-binding EGF-like growth factor accelerates keratinocyte migration and skin wound healing

TLDR
It is demonstrated, for the first time, that HB-EGF is the predominant growth factor involved in epithelialization in skin wound healing in vivo and that it functions by accelerating keratinocyte migration, rather than proliferation.

Activation of HER4 by heparin‐binding EGF‐like growth factor stimulates chemotaxis but not proliferation

TLDR
Heparin‐binding epidermal growth factor‐like growth factor can activate two EGF receptor subtypes, HER1 and HER4, but with different biological responses, and is a potent chemotactic factor for cells overexpressing HER4.

Heparin-binding EGF-like growth factor and ErbB signaling is essential for heart function

TLDR
It was concluded that HB-EGF activation of receptor tyrosine kinases is essential for normal heart function.
...